Cancer-specific MALDI-TOF profiles of blood serum and plasma: Biological meaning and perspectives

Journal of Proteomics

Volumn 73, Issue 3, 2010, Pages 537-551

  Karpova, M A ^a   Moshkovskii, S A ^a   Toropygin, I Y ^a   Archakov, A I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Acute phase proteins; Biomarker; Cancer; MALDI TOF MS

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID A PROTEIN; APOLIPOPROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; CYSTATIN C; EXOPEPTIDASE; HAPTOGLOBIN; PEPTIDE FRAGMENT; PREALBUMIN; TRANSFERRIN; TRYPSIN;

AMINO ACID SEQUENCE; BONE METASTASIS; BREAST CANCER; CHROMATOGRAPHY; COLON CANCER; COLORECTAL CANCER; ENZYME ACTIVITY; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PANCREAS CANCER; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SERUM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; HUMANS; METABOLOME; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE HYDROLASES; PLASMA; PROTEASE INHIBITORS; SERUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 72149087954     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2009.09.011     Document Type: Review

References (147)

1. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 3 4 (2003) 243-252
2. Omenn G.S. Strategies for plasma proteomic profiling of cancers. Proteomics 6 20 (2006) 5662-5673
3. Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22 20 (2004) 4059-4066
4. Simpson R.J., Bernhard O.K., Greening D.W., and Moritz R.L. Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 12 1 (2008) 72-77
5. Whelan L.C., Power K.A., McDowell D.T., Kennedy J., and Gallagher W.M. Applications of SELDI-MS technology in oncology. J Cell Mol Med 12 5A (2008) 1535-1547
6. Whiteley G.R., Colantonio S., Sacconi A., and Saul R.G. Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin Lab Med 29 1 (2009) 57-69
7. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52 7 (2006) 1223-1237
8. Archakov A.I., Ivanov Y.D., Lisitsa A.V., and Zgoda V.G. AFM fishing nanotechnology is the way to reverse the Avogadro number in proteomics. Proteomics 7 1 (2007) 4-9
9. Villanueva J., Philip J., DeNoyer L., and Tempst P. Data analysis of assorted serum peptidome profiles. Nat Protoc 2 3 (2007) 588-602
10. Listgarten J., and Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 4 4 (2005) 419-434
11. Timms J.F., Arslan-Low E., Gentry-Maharaj A., Luo Z., T'Jampens D., Podust V.N., et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 53 4 (2007) 645-656
12. Luque-Garcia J.L., and Neubert T.A. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J Chromatogr A 1153 1-2 (2007) 259-276
13. Baumann S., Ceglarek U., Fiedler G.M., Lembcke J., Leichtle A., and Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 51 6 (2005) 973-980
14. Haab B.B., Geierstanger B.H., Michailidis G., Vitzthum F., Forrester S., Okon R., et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 5 13 (2005) 3278-3291
15. Petricoin E.F., and Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15 1 (2004) 24-30
16. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
17. Zhu W., Wang X., Ma Y., Rao M., Glimm J., and Kovach J.S. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 100 25 (2003) 14666-14671
18. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100 21 (2003) 12343-12348
19. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., and Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 17 (2005) 4589-4596
20. Vlahou A., Schorge J.O., Gregory B.W., and Coleman R.L. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol 2003 5 (2003) 308-314
21. McLerran D., Grizzle W.E., Feng Z., Thompson I.M., Bigbee W.L., Cazares L.H., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 54 1 (2008) 53-60
22. Wei Y.S., Zheng Y.H., Liang W.B., Zhang J.Z., Yang Z.H., Lv M.L., et al. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 112 3 (2008) 544-551
23. Zinkin N.T., Grall F., Bhaskar K., Otu H.H., Spentzos D., Kalmowitz B., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 14 2 (2008) 470-477
24. Tolson J., Bogumil R., Brunst E., Beck H., Elsner R., Humeny A., et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84 7 (2004) 845-856
25. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Chen D.S., et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6 9 (2006) 2865-2873
26. Zhang Z., Bast Jr. R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 16 (2004) 5882-5890
27. Ward D.G., Suggett N., Cheng Y., Wei W., Johnson H., Billingham L.J., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94 12 (2006) 1898-1905
28. Miguet L., Bogumil R., Decloquement P., Herbrecht R., Potier N., Mauvieux L., et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res 5 9 (2006) 2258-2269
29. Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.L., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 11 3 (2005) 1073-1085
30. Escher N., Kaatz M., Melle C., Hipler C., Ziemer M., Driesch D., et al. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia 9 3 (2007) 254-259
31. Chang J.T., Chen L.C., Wei S.Y., Chen Y.J., Wang H.M., Liao C.T., et al. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 39 12 (2006) 1144-1151
32. Cheng A.J., Chen L.C., Chien K.Y., Chen Y.J., Chang J.T., Wang H.M., et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51 12 (2005) 2236-2244
33. Freed G.L., Cazares L.H., Fichandler C.E., Fuller T.W., Sawyer C.A., Stack Jr. B.C., et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope 118 1 (2008) 61-68
34. Villanueva J., Philip J., Entenberg D., Chaparro C.A., Tanwar M.K., Holland E.C., et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76 6 (2004) 1560-1570
35. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5 10 (2006) 1840-1852
36. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116 1 (2006) 271-284
37. Goldman R., Ressom H.W., Abdel-Hamid M., Goldman L., Wang A., Varghese R.S., et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis 28 10 (2007) 2149-2153
38. Orvisky E., Drake S.K., Martin B.M., Abdel-Hamid M., Ressom H.W., Varghese R.S., et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 6 9 (2006) 2895-2902
39. Whiteaker J.R., Zhang H., Eng J.K., Fang R., Piening B.D., Feng L.C., et al. Head-to-head comparison of serum fractionation techniques. J Proteome Res 6 2 (2007) 828-836
40. Zolotarjova N., Martosella J., Nicol G., Bailey J., Boyes B.E., and Barrett W.C. Differences among techniques for high-abundant protein depletion. Proteomics 5 13 (2005) 3304-3313
41. Hortin G.L., Jortani S.A., Ritchie Jr. J.C., Valdes Jr. R., and Chan D.W. Proteomics: a new diagnostic frontier. Clin Chem 52 7 (2006) 1218-1222
42. Goufman E.I., Moshkovskii S.A., Tikhonova O.V., Lokhov P.G., Zgoda V.G., Serebryakova M.V., et al. Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Mosc) 71 4 (2006) 354-360
43. Echan L.A., Tang H.Y., Ali-Khan N., Lee K., and Speicher D.W. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5 13 (2005) 3292-3303
44. Huang L., Harvie G., Feitelson J.S., Gramatikoff K., Herold D.A., Allen D.L., et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5 13 (2005) 3314-3328
45. Fu Q., Bovenkamp D.E., and Van Eyk J.E. A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis. Methods Mol Biol 357 (2007) 365-371
46. Geho D.H., Liotta L.A., Petricoin E.F., Zhao W., and Araujo R.P. The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol 10 1 (2006) 50-55
47. Lowenthal M.S., Mehta A.I., Frogale K., Bandle R.W., Araujo R.P., Hood B.L., et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51 10 (2005) 1933-1945
48. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., and Veenstra T.D. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2 10 (2003) 1096-1103
49. Zhou M., Lucas D.A., Chan K.C., Issaq H.J., Petricoin III E.F., Liotta L.A., et al. An investigation into the human serum "interactome". Electrophoresis 25 9 (2004) 1289-1298
50. Gundry R.L., F. Q., Jelinek C.A., Van Eyk J.E., J., and C. R. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl 1 (2007) 73-88
51. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin III E.F., and Liotta L.A. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 53 6 (2007) 1067-1074
52. Kikuchi S., Honda K., Handa Y., Kato H., Yamashita K., Umaki T., et al. Serum albumin-associated peptides of patients with uterine endometrial cancer. Cancer Sci 98 6 (2007) 822-829
53. Liu C., Shea N., Rucker S., Harvey L., Russo P., Saul R., et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 7 22 (2007) 4045-4052
54. German D.C., Gurnani P., Nandi A., Garner H.R., Fisher W., Diaz-Arrastia R., et al. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed Pharmacother 61 7 (2007) 383-389
55. Villanueva J., Nazarian A., Lawlor K., Yi S.S., Robbins R.J., and Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol Cell Proteomics 7 3 (2008) 509-518
56. Fung E.T., Yip T.T., Lomas L., Wang Z., Yip C., Meng X.Y., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115 5 (2005) 783-789
57. Song J., Patel M., Rosenzweig C.N., Chan-Li Y., Sokoll L.J., Fung E.T., et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52 6 (2006) 1045-1053
58. Matharoo-Ball B.R.L., Lancashire L., Ugurel S., Miles A.K., Weston D.J., Rees R., et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin Appl 1 6 (2007) 605-620
59. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
60. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 7092 (2006) 431-436
61. Rakoff-Nahoum S. Why cancer and inflammation?. Yale J Biol Med 79 3-4 (2006) 123-130
62. Lasztity N., Biro L., Nemeth E., Pap A., and Antal M. Protein status in pancreatitis-transthyretin is a sensitive biomarker of malnutrition in acute and chronic pancreatitis. Clin Chem Lab Med 40 12 (2002) 1320-1324
63. Raguso C.A., Dupertuis Y.M., and Pichard C. The role of visceral proteins in the nutritional assessment of intensive care unit patients. Curr Opin Clin Nutr Metab Care 6 2 (2003) 211-216
64. Kravitz M.S., Pitashny M., and Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 25 6 (2005) 582-591
65. Burger D., and Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev 1 1-2 (2002) 111-117
66. Moore L.E., Fung E.T., McGuire M., Rabkin C.C., Molinaro A., Wang Z., et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 15 9 (2006) 1641-1646
67. Engwegen J.Y., Helgason H.H., Cats A., Harris N., Bonfrer J.M., Schellens J.H., et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 12 10 (2006) 1536-1544
68. Ehmann M., Felix K., Hartmann D., Schnolzer M., Nees M., Vorderwulbecke S., et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34 2 (2007) 205-214
69. Huang H.L., Stasyk T., Morandell S., Dieplinger H., Falkensammer G., Griesmacher A., et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27 8 (2006) 1641-1650
70. Steel L.F., Shumpert D., Trotter M., Seeholzer S.H., Evans A.A., London W.T., et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3 5 (2003) 601-609
71. Mahley R.W., Innerarity T.L., Rall Jr. S.C., and Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25 12 (1984) 1277-1294
72. Berbee J.F., van der Hoogt C.C., Kleemann R., Schippers E.F., Kitchens R.L., van Dissel J.T., et al. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. Faseb J 20 12 (2006) 2162-2164
73. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 41 11 (2004) 1089-1098
74. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 38 2-3 (2001) 175-187
75. Li J., Orlandi R., White C.N., Rosenzweig J., Zhao J., Seregni E., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51 12 (2005) 2229-2235
76. Van Vlierberghe H., Langlois M., and Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 345 1-2 (2004) 35-42
77. Wassell J. Haptoglobin: function and polymorphism. Clin Lab 46 11-12 (2000) 547-552
78. Fujimura T., Shinohara Y., Tissot B., Pang P.C., Kurogochi M., Saito S., et al. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 122 1 (2008) 39-49
79. Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., and Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 7 23 (2007) 4292-4302
80. Chen C.B., Su Y.C., Huang T.T., Ho H.C., Chang Y.T., Tung Y.T., et al. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clin Chim Acta 398 1-2 (2008) 48-52
81. Hoagland L.F.T., Campa M.J., Gottlin E.B., Herndon II J.E., and Patz Jr. E.F. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110 10 (2007) 2260-2268
82. Rai A.J., Zhang Z., Rosenzweig J., Shih Ie M., Pham T., Fung E.T., et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126 12 (2002) 1518-1526
83. Uhlar C.M., and Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265 2 (1999) 501-523
84. Biran H., Friedman N., Neumann L., Pras M., and Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39 7 (1986) 794-797
85. Rosenthal C.J., and Sullivan L.M. Serum amyloid A to monitor cancer dissemination. Ann Intern Med 91 3 (1979) 383-390
86. Kaneti J., Winikoff Y., Zimlichman S., and Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 12 5 (1984) 239-241
87. Glojnaric I., Casl M.T., Simic D., and Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39 2 (2001) 129-133
88. Chan D.C., Chen C.J., Chu H.C., Chang W.K., Yu J.C., Chen Y.J., et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 14 1 (2007) 84-93
89. Moshkovskii S.A., Serebryakova M.V., Kuteykin-Teplyakov K.B., Tikhonova O.V., Goufman E.I., Zgoda V.G., et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5 14 (2005) 3790-3797
90. Gao W.M., Kuick R., Orchekowski R.P., Misek D.E., Qiu J., Greenberg A.K., et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5 (2005) 110
91. Liu D.H., Wang X.M., Zhang L.J., Dai S.W., Liu L.Y., Liu J.F., et al. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci 20 1 (2007) 33-40
92. Cho W.C., Yip T.T., Yip C., Yip V., Thulasiraman V., Ngan R.K., et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10 1 Pt 1 (2004) 43-52
93. Le L., Chi K., Tyldesley S., Flibotte S., Diamond D.L., Kuzyk M.A., et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51 4 (2005) 695-707
94. Urieli-Shoval S., Cohen P., Eisenberg S., and Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 46 12 (1998) 1377-1384
95. Gutfeld O., Prus D., Ackerman Z., Dishon S., Linke R.P., Levin M., et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 54 1 (2006) 63-73
96. Kovacevic A., Hammer A., Sundl M., Pfister B., Hrzenjak A., Ray A., et al. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett 580 1 (2006) 161-167
97. Malle E., Sodin-Semrl S., and Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci (2008)
98. Vlasova M.A., and Moshkovskii S.A. Molecular interactions of acute phase serum amyloid A: possible involvement in carcinogenesis. Biochemistry (Mosc) 71 10 (2006) 1051-1059
99. He R., Sang H., and Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101 4 (2003) 1572-1581
100. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115 10 (2005) 2625-2632
101. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 1 (2001) 14-23
102. Michaeli A., Finci-Yeheskel Z., Dishon S., Linke R.P., Levin M., and Urieli-Shoval S. Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun 368 2 (2008) 368-373
103. Konukoglu D., Turhan M.S., Celik V., and Turna H. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res 125 6 (2007) 747-751
104. Beyer B.C., Heiss M.M., Simon E.H., Gruetzner K.U., Babic R., Jauch K.W., et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106 5 (2006) 1026-1035
105. Shariat S.F., Roehrborn C.G., McConnell J.D., Park S., Alam N., Wheeler T.M., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25 4 (2007) 349-355
106. Steiner E., Pollow K., Hasenclever D., Schormann W., Hermes M., Schmidt M., et al. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol 108 3 (2008) 569-576
107. Annecke K., Schmitt M., Euler U., Zerm M., Paepke D., Paepke S., et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45 (2008) 31-45
108. Dhainaut J.F., Marin N., Mignon A., and Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29 7 Suppl (2001) S42-S47
109. El-Akawi Z.J., Al-Hindawi F.K., and Bashir N.A. Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro Endocrinol Lett 29 4 (2008)
110. Chen Y., Lim B.K., Peh S.C., Abdul-Rahman P.S., and Hashim O.H. Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma. Proteome Sci 6 (2008) 20
111. Koomen J.M., Shih L.N., Coombes K.R., Li D., Xiao L.C., Fidler I.J., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11 3 (2005) 1110-1118
112. Hiemstra P.S. Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 30 2 (2002) 116-120
113. Tamir S., Kadner S.S., Katz J., and Finlay T.H. Regulation of antitrypsin and antichymotrypsin synthesis by MCF-7 breast cancer cell sublines. Endocrinology 127 3 (1990) 1319-1328
114. Sun Z., and Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 5 3 (2004) 182-190
115. Benkmann H.G., Hanssen H.P., Ovenbeck R., and Goedde H.W. Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered 37 5 (1987) 290-293
116. Graziadei I., Gaggl S., Kaserbacher R., Braunsteiner H., and Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 83 1 (1994) 260-268
117. Yavelow J., Tuccillo A., Kadner S.S., Katz J., and Finlay T.H. Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells. J Clin Endocrinol Metab 82 3 (1997) 745-752
118. Petrache I., Fijalkowska I., Medler T.R., Skirball J., Cruz P., Zhen L., et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 169 4 (2006) 1155-1166
119. Dabbagh K., Laurent G.J., Shock A., Leoni P., Papakrivopoulou J., and Chambers R.C. Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol 186 1 (2001) 73-81
120. Palha J.A. Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med 40 12 (2002) 1292-1300
121. Ingenbleek Y., and Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 14 (1994) 495-533
122. Bernstein L.H., and Ingenbleek Y. Transthyretin: its response to malnutrition and stress injury. Clinical usefulness and economic implications. Clin Chem Lab Med 40 12 (2002) 1344-1348
123. Devakonda A., George L., Raoof S., Esan A., Saleh A., and Bernstein L.H. Transthyretin as a marker to predict outcome in critically ill patients. Clin Biochem (2008)
124. Mahlck C.G., and Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest 37 2 (1994) 135-140
125. Geisler J.P., Linnemeier G.C., Thomas A.J., and Manahan K.J. Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 106 1 (2007) 128-131
126. Yildiz P.B., Shyr Y., Rahman J.S., Wardwell N.R., Zimmerman L.J., Shakhtour B., et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2 10 (2007) 893-901
127. Roberts D., Williams S.J., Cvetkovic D., Weinstein J.K., Godwin A.K., Johnson S.W., et al. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol 21 1 (2002) 11-19
128. van Bennekum A.M., Wei S., Gamble M.V., Vogel S., Piantedosi R., Gottesman M., et al. Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. J Biol Chem 276 2 (2001) 1107-1113
129. Gomme P.T., McCann K.B., and Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 10 4 (2005) 267-273
130. Vostrejs M., Moran P.L., and Seligman P.A. Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation. J Clin Invest 82 1 (1988) 331-339
131. Morrone G., Corbo L., Turco M.C., Pizzano R., De Felice M., Bridges S., et al. Transferrin-like autocrine growth factor, derived from T-lymphoma cells, that inhibits normal T-cell proliferation. Cancer Res 48 12 (1988) 3425-3429
132. Fassl S., Leisser C., Huettenbrenner S., Maier S., Rosenberger G., Strasser S., et al. Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNFalpha, FasL, TRAIL, or Myc. Oncogene 22 51 (2003) 8343-8355
133. Carlevaro M.F., Albini A., Ribatti D., Gentili C., Benelli R., Cermelli S., et al. Transferrin promotes endothelial cell migration and invasion: implication in cartilage neovascularization. J Cell Biol 136 6 (1997) 1375-1384
134. Ahmed N., Oliva K.T., Barker G., Hoffmann P., Reeve S., Smith I.A., et al. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5 17 (2005) 4625-4636
135. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235 2 (2006) 159-176
136. Kyhse-Andersen J., Schmidt C., Nordin G., Andersson B., Nilsson-Ehle P., Lindstrom V., et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40 10 (1994) 1921-1926
137. Kos J., Stabuc B., Cimerman N., and Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44 12 (1998) 2556-2557
138. Mulaomerovic A., Halilbasic A., Cickusic E., Zavasnik-Bergant T., Begic L., and Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett 248 2 (2007) 192-197
139. DeClerck Y.A., Mercurio A.M., Stack M.S., Chapman H.A., Zutter M.M., Muschel R.J., et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164 4 (2004) 1131-1139
140. Lopez-Otin C., and Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7 10 (2007) 800-808
141. Petricoin E.F., Belluco C., Araujo R.P., and Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6 12 (2006) 961-967
142. Sitek B., Sipos B., Alkatout I., Poschmann G., Stephan C., Schulenborg T., et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res 8 4 (2009) 1647-1656
143. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Mohring T., et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5 13 (2005) 3414-3422
144. Faca V, Krasnoselsky A, Hanash S. Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 2007;43(3):279, 281-3, 285.
145. Gobel T., Vorderwulbecke S., Hauck K., Fey H., Haussinger D., and Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 12 47 (2006) 7604-7612
146. Dai S., Wang X., Liu L., Liu J., Wu S., Huang L., et al. Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 50 3 (2007) 305-311
147. Hortin G.L., Sviridov D., and Anderson N.L. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 54 10 (2008) 1608-1616